08:39 EST Gilead drops 11% in premarket trading after Phase 3 study fails to meet endpoint
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Day One Biopharmaceuticals announces two new appointments to board
- Arcus Biosciences announces ‘promising’ ARC-8 Phase 1b study data
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Gilead stock could finally have breakout year, Barron’s says
- Biotech Alert: Searches spiking for these stocks today